Meta-analyses of global trials finds in favor of aromatase inhibitors

(Mayo Clinic) Two separate meta-analyses of clinical trials from around the world that tested tamoxifen against aromatase inhibitor drugs in postmenopausal women with early breast have each reached the same conclusion: aromatase inhibitors are more effective in preventing breast from coming back. Patients using aromatase inhibitors had more than a 3 percent lower recurrence 6-8 years after diagnosis, compared to women using tamoxifen alone.


Read more

Related posts

Leave a Reply